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Abstract
Background: Vulvodynia has been considered to be a chronic disorder. We sought to estimate the probability of
and risk factors for remission, relapse, and persistence among women screening positive for vulvodynia.
Methods: Survey-based assessment in a longitudinal population-based study of women (the Woman to Woman
Health Study) who screened positive for vulvodynia and completed at least four follow-up surveys. Outcome
measures included remission without relapse, relapse (after remission), and persistence of a positive vulvodynia
screen. Multinomial regression was used to assess factors associated with outcomes.
Results: Of 441 women screening positive for vulvodynia during the study, 239 completed 4 additional surveys.
Of these, 23 (9.6%) had consistently positive vulvodynia screens, 121 (50.6%) remitted without relapse, and 95
(39.7%) relapsed following remission. Overall, factors associated with both relapse and persistence (compared
with remission alone) included increased severity of pain ever ( p< 0.001) or after intercourse ( p= 0.03), longer
duration of symptoms ( p £ 0.001), and screening positive for fibromyalgia ( p < 0.001). Factors associated with
persistence (but not relapse) included more severe symptoms with intercourse ( p= 0.001) and pain with oral sex
( p = 0.003) or partner touch ( p= 0.04). Factors associated with relapse (but not persistence) included having
provoked pain ( p= 0.001) or screening positive for interstitial cystitis ( p= 0.05) at first positive vulvodynia
screen. Demographic characteristics, age at pain onset, and whether vulvodynia was primary or secondary did not
predict outcome.
Conclusion: Remission of vulvodynia symptoms is common with approximately half of remitters experiencing
a relapse within 6–30 months. Persistence without remission is the exception rather than the rule. Pain history
and comorbid conditions were associated with the more severe outcomes of relapse and/or persistence com-
pared with those who remitted only. These findings provide further support that vulvodynia is heterogeneous
and often occurs in an episodic pattern.
Introduction
Vulvodynia has long been understood to be achronic condition. With a prevalence of 8.3% and an an-
nual incidence of *4.2% per 100 woman-years, it poses a
considerable burden to women’s health.1 Until recently, it was
thought that once vulvodynia developed it would persist.2–4 A
limited number of studies now have included a follow-up eval-
uation andhave documented that not allwomenwith vulvodynia
continue to report such symptoms at follow-up, suggesting
that remission does occur.5–7 Clinical experience suggests
that women who experience remission remain at high risk of
relapsing symptoms. However, the rates of persistence, remis-
sion, and relapse are currently unknown, and the factors asso-
ciatedwith these clinical trajectories have not been investigated.
Retrospective recall of symptoms suggestive of vulvody-
nia is likely biased as women often fail to recall prior pain
documented at an earlier visit.7 We conducted a prospective
study to more accurately measure the presence and absence
of symptoms suggesting vulvodynia over time and to assess
the frequency of persistence, remission, and relapse in a
population-based study. A population-based approach cap-
tures the breadth of vulvodynia symptoms and clinical course
present in the community. We previously reported on the
prevalence and incidence of vulvodynia in a population-
based longitudinal study of women in southeast Michigan.1,8
This report describes further analyses demonstrating the rates
of persistence, remission, and relapse of vulvodynia among
those screening positive for the disorder and risk factors as-
sociated with these clinical trajectories.
1Department Family Medicine, University of Michigan, Ann Arbor, Michigan.
Departments of 2Epidemiology and 3Biostatistics, School of Public Health, University of Michigan, Ann Arbor, Michigan.
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Materials and Methods
The study was approved by the University of Michigan
IRB. Methods for enrollment and sampling probabilities have
been published previously.1 In brief, a population-based
sample of women aged 18 years and older living in a four-
county area in southeastMichiganwere enrolled by the Survey
Research Operations at the Institute for Social Research at the
University ofMichiganWoman toWomanHealth Study using
random digit dialing.
After giving oral informed consent and completing a short
interview, participants were sent a 26-page survey, which
included a previously validated screen for vulvodynia as well
as questions about women’s demographic characteristics,
health history, exposures, current symptoms, and other po-
tential risk factors. The survey also included a limited set of
screens for other pain and psychological conditions, includ-
ing those for fibromyalgia, interstitial cystitis, irritable bowel
disorder, depression, and post-traumatic stress disorder
(PTSD). Those completing the baseline survey were sent
additional follow-up surveys every 6 months. A small sti-
pend, varying from $5 for the initial survey to $25 for the 36-
month follow-up survey, was given to the participants. This
report is based on information obtained from baseline
through the 36-month follow-up survey.
Eligibility
Of the 2,542 women enrolled in the Woman to Woman
Health Study, eligible women had to have completed the
baseline comprehensive survey, including all questions nec-
essary for the vulvodynia screen. Because the possibility of
relapse was increasing over time, only the data for those with
at least four additional surveys are presented for remission
and relapse rates and factors associated with outcomes to
provide a consistent yet maximum follow-up period for each
included participant.
Definitions
The vulvodynia screen used was verified previously9 and
includes the current presence of pain at the opening to the va-
gina with or without provocation that has been present for at
least 3 months and has not resolved. Remission was defined as
no longer meeting criteria for vulvodynia following a positive
screen. Relapse was defined as again screening positive for
vulvodynia following such a remission. Persistence was defined
when awoman continued to have positive vulvodynia screens at
every follow-up subsequent to the initial positive screen.
The screens used for other comorbid pain and psycho-
logical conditions included the: Fibromyalgia Impact Ques-
tionnaire for fibromyalgia,10,11 Rice High Specificity
definition for interstitial cystitis,12 Rome II criteria for irri-
table bowel syndrome (IBS),13,14 PHQ-8 for depression,15,16
and PC-PTSD for PTSD.17
Primary vulvodynia was defined as those who either had
their vulvar pain with first intercourse or first tampon use or,
if these data were incomplete, if they reported their vulvar
pain began before the age of 20.
Analysis
Frequencies were assessed for all variables used in the
analysis. Because the clinical outcome could change over the
course of the study (with increasing numbers of women
demonstrating a relapse), the clinical outcome measures of
remission, relapse, and persistence were determined based on
the results of the vulvodynia screens on two, three, and four
surveys completed following the first positive screen. There-
after, the analyses were conducted using the data for those with
at least four surveys completed after the first positive survey to
maximize the time followed and tomaintain consistency in the
number of follow-up surveys analyzed.
For the analyses of remission and relapse rates, Poisson
regression analysis was performed using data from the time
of the initial positive vulvodynia screen to calculate remis-
sion rates and from time of first remission to calculate re-
lapse rates. Chi square analysis was used to determine the
relationship between clinical outcome and whether the par-
ticipant was currently taking a medication for pain or for
depression.
The association between potential risk factors and the ca-
tegories of remission without relapse, relapse, and persis-
tence was assessed usingmultinomial logistic regression with
potential risk factors, measured at the time of a first positive
vulvodynia screen, included as covariates, controlling for
age. Odds ratios for all pairwise comparisons of relapse
versus remission, persistence versus remission, and persis-
tence versus relapse were determined.
Results
Eligibility
Of the 2,542 women enrolled in the Woman to Woman
Health Study, 267 did not complete the baseline comprehen-
sive survey and an additional 82 did not complete all questions
necessary for the vulvodynia screen—leaving a total of 2,193
potential participants for this analysis, 1,763 (80.4%) of whom
were still participating at the 36-month survey. Of the 2,193
women, 441 screened positive for vulvodynia either at baseline
(n= 238) or on one of the subsequent five follow-up surveys
(n= 203). The average number of surveys completed overall
for the 441 cases was 5.3– 1.4 (median= 6, mode= 6). Of the
441 women screening positive, 347 (78.7%) had at least two
surveys completed after being categorized as a case, 302
(68.5%) completed a minimum of three surveys after the first
positive survey, and 239 (54.2%) completed four surveys and
were included in the analyses.
Women excluded from the analyses because of insufficient
follow-up after becoming a case did not differ in age (45.6 vs.
46.3 years, p= 0.67), ethnic/racial group (74.5% vs. 83.0%
white, nonHispanic, p= 0.17), marital status (71.0% vs.
77.7% married or living as married, p = 0.17), household in-
come >$60,000 (56.2% vs. 61.8%, p = 0.46), or college
graduation (52.1% vs. 55.9%, p = 0.51) compared with wo-
men included in the analysis.
Remission, relapse, and persistence prevalence
The proportions of women who demonstrated a remission
without relapse, a relapse, or persistence of a positive screen
varied, depending on how many follow-up surveys were
completed or considered in the analysis (Fig. 1). The remis-
sion rate was substantial (67.1% within two surveys of the
initial positive survey), but over time, more than half of
women who reported remission had a relapse.
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Because of the increasing proportion of women demon-
strating a relapse based on the number of surveys completed,
we limited the variability and maximized the time followed
for each woman by limiting the further analyses to those
completing four surveys after the first positive screen.
Among the 239 women with a positive screen for vulvo-
dynia with at least four follow-up surveys completed, 121
(50.6%) had a remission without relapse, 95 (39.7%) had a
remission with relapse documented, and 23 (9.6%) persisted
throughout the time observed by follow-up surveys. The
clinical course did not differ by demographic characteristics
of the women, including age, ethnicity, or ability to pay for
basics (food, shelter), although those with persistent symp-
toms were more likely to be married (Table 1).
Since the probability of remission soon after screening
positive was high, we assessed whether remission was more
likely to be observed when women became positive on a
survey after the baseline survey, as opposed to when they
screened positive at the baseline survey. Regardless of which
survey contained the initial positive vulvodynia, we found
that the majority of observed remissions occurred at the
following survey (data not shown).
Rates of remission and relapse
Among the 239 women screening positive for vulvodynia
and having four additional follow-up surveys, the average
time followed was 593.3 – 62.2 days (median 575 days), and
216 (90.3%) had a remission during that time. The remission
rate adjusted for time followed until remission occurred was
88.6 cases per 100 woman-years (95% CI 77.6, 100.0) over
the 3 years of the study. No difference in remission rates were
noted when stratified by age or ethnicity, but the remission
rate was less (82.0 cases/100 woman-years [95% CI 70.7,
95.1]) in those currently married or living as married.
Of the 216 women with a remission who completed at least
one further survey, (i.e., did not have their remission on the
fourth survey following the first positive screen) 111 (51.3%)
had subsequently relapsed, with a relapse rate over the re-
maining surveys of 32.4 cases per 100 woman-years (95% CI
26.9, 39.1) following remission. The rate of relapse after a
remission was not associated with age, ethnicity, or marital
status.
Women often denied having had symptoms that they had
reported on earlier surveys. Among the 103 women who had
initially reported vulvar pain and subsequently had a remis-
sion, 39 (37.9%) reported no history of vulvar pain at their
follow-up visit. However, the probability a woman would
screen positive again (relapse) on a subsequent survey versus
reporting no further vulvar symptoms was equally likely
whether the participant had confirmed her previously re-
ported vulvar pain (46.9%) or not (41.0%, p = 0.68).
Factors associated with vulvodynia remission,
relapse, or persistence
The relationship between potential factors associated with
remission, relapse, and persistence was assessed using mul-
tinomial regression, controlling for age. Women with re-
mission, relapse, or persistence did not differ by health rating,
rating of physical pain in general, or general pain interference
as reported at the time of the first positive vulvodynia screen
( p > 0.05, data not shown). However, prognosis was associ-
ated with a number of factors (Table 2).
If the pain was described as provoked, women had in-
creased odds of having recurrent vulvodynia and were less
likely to remit. Both pain with intercourse and pain after
intercourse were associated with relapse and persistence.
Pain with oral sex, masturbation, and having an orgasm were
not commonly reported; however, those with pain with oral
sex or with partner touch were more likely to persist. The
more severe the rating of the worst pain ever and the longer
the pain had been present were associated with greater odds
of relapse and persistence. However, neither the age at onset
of pain nor whether the pain was primary or secondary was
associated with relapse or persistence. Pain quality (sharp,
stabbing, burning, or itching) was not associated with prog-
nosis (data not shown).
Comorbid pain conditions are known to be associated with
vulvodynia,18–21 and in fact, the presence of fibromyalgia and
interstitial cystitis, but not IBS, at the time of first positive
vulvodynia screen was associated with the increased odds of
persistence compared with either remission or relapse. Simi-
larly, screening positive for depression, but not for PTSD, at the
time of first positive vulvodynia screen was associated with
more persistent vulvodynia than if the screen was negative.
FIG. 1. Proportions with remission without relapse, relapse
following remission, or persistence.
Table 1. Demographic Characteristics
(at Study Entry) Stratified by Outcome
Among Those Participants with Four or More
Completed Surveys Following a Positive
Vulvodynia Screen (n= 239)
Characteristics
Remission
121
(50.6%)
Relapse
95
(39.7%)
Persist
23
(9.6%) p
Age (mean – SD
in years)
47.6 – 14.6 47.1 – 13.6 48.2 – 11.8 0.93
Ethnicity 0.49
White 86.8% 82.1% 78.3%
Black 5.8% 10.5% 4.3%
Hispanic 3.3% 2.1% 8.7%
Other 4.1% 5.3% 8.7%
Married or living
as married
78.5% 80.9% 100.0% 0.05
Hard to pay
for basics
40.2% 33.7% 34.8% 0.61
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To assess whether restriction of analyses to women with
four follow-up visits biased study results, we reran analyses
based on having at least two and at least three follow-up visits
(which limits the opportunity for a relapse to be observed).
Results using these data did not differ substantively from
those presented here (data not shown).
Association with current treatment and outcome
Rarely have studies assessing remission reported on cur-
rent medications being taken by those reporting symptoms or
lack of symptoms. We assessed whether the participants re-
ported taking medication at the time of first positive screen or
at the time of first remission that might alter vulvar pain.
These included those used for pain or the neurotransmitter-
altering drugs commonly used for psychological issues.
Clinical outcome was not associated with use of medica-
tions for pain or neurotransmitter-altering drugs ( p > 0.29). In
addition, when asked whether they were on a treatment for
the vulvar pain, only 30 (12.5%) reported taking medications
(or combinations of two medications) at the time of their
first positive screen. Reported treatments included estrogen –
progesterone in 50.0% (15/30), antifungals in 13.3% (4/30),
topical steroids in 20.0% (6/30), topical cream or moisturizer
in 23.3% (7/30), and miscellaneous treatments in 13.3% (4/
30). None were on antidepressants, pain medication, or an-
ticonvulsants for their vulvar pain.
Discussion
This is one of the first longitudinal population-based
studies to prospectively determine probabilities of remission,
relapse, and persistence among women screening positive for
vulvodynia. We found the probability of remission was quite
high, but approximately half of those whose symptoms re-
solved had a relapse of symptoms within a short period of
time. Persistence of symptoms at every screening was only
present in *10% of those with a positive survey who were
followed for at least four additional surveys.
Vulvodynia has traditionally been considered to be a
chronic disorder, with little recognition of remissions or re-
lapse. Peckham was one of the first to report remission after a
woman was diagnosed with having vulvodynia: over 15
years, 50% of his 67 cases reported no further symptoms,
with most remissions occurring in the first 6 months after
diagnosis.22 Furthermore, studies assessing nonclinic-based
populations suggest that a substantial proportion of women
who report past vulvodynia deny ongoing symptoms.1,6,23,24
Cross-sectional surveys conducted online,25 in a population-
based survey conducted in the Boston area,23 and in the initial
survey of this longitudinal population-based study of vulvo-
dynia1 estimated that 16%–27.9% of the populations had met
survey-based criteria for vulvodynia at some point, but only
1.7%–8.3% reported current symptoms, suggesting remis-
sion could occur in a substantial proportion of sufferers.
Sutton et al. reported a remission rate of 31.4% at a 1-year
follow-up, but if all those who hadmet criteria for vulvodynia
at the initial screen who denied symptoms at the 1-year
follow-up were included in the analysis, a remission rate of
66.7% (48/72 women) would be seen.7 Nguyen et al. ques-
tioned women with screened and verified vulvodynia about
periods in the past in which vulvar pain resolved (remission)
and reported an overall remission rate of 33.0% (46/138).26
However, by design, all women in their study had vulvar pain
consistent with vulvodynia and hence all with a remission had
subsequently relapsed, whereby those without a relapse would
not have been within their study population. More recently,
Davis et al. found that when assessing response to treatment
for vulvodynia over a 2-year period, women tended to report
less pain within this time frame independent of treatment used
(physical therapy, medical or surgical treatment, acupuncture,
etc.) or if no treatment was used at all, although none were
reported to have gone into remission.27
Inconsistent reporting of the history of vulvar symptoms,
in which previously reported symptoms were later denied
and/or forgotten, has been noted in two prospective studies of
vulvodynia and was again confirmed in the current study. In
one of the first prospective assessments of vulvodynia re-
mission, Reed et al. reported a 22.2% remission rate over 2
years among women identified from a Women’s Health
Registry, 60% of whom denied previous symptoms consis-
tent with vulvodynia, despite having screened positive (with
a subset validated clinically) 2 years previously.6 Similarly,
in a nationwide population-based study, Sutton et al. found
that 37 of 72 women meeting criteria for vulvodynia at their
baseline survey denied ever having had these symptoms
when asked a year later (51.4%).7 We considered women with
symptoms that resolved to have remitted in our analysis—even
when they reported no previous symptoms, while Sutton et al.
excluded these women from their analysis, thereby explaining
the lower remission rate (31.4%) they reported.
Some women who report resolution of vulvodynia symp-
toms may be taking medications for other disorders (e.g., de-
pression, anxiety, fibromyalgia, or interstitial cystitis) that may
impact their vulvar neuropathic pain symptoms in some pa-
tients.28–31 We found that very few women were being treated
for their vulvar pain, with the most likely treatment being
topical estrogen– progesterone. Treatments were not associ-
ated with remission or relapse. However, no one reported
treatment with the two classes of medications often used for
neuropathic pain—antidepressants and anticonvulsants—and
hence no conclusions can be drawn regarding the impact these
medications might have on remission/relapse.30,31
Relapse in vulvodynia
Previous studies have not had the prospective data needed
to report on the likelihood of relapse. We have demonstrated
that although remission of symptoms to a level no longer
meeting criteria for vulvodynia is quite common, relapse of
symptoms within a short time period occurs in roughly half of
these cases. With even longer follow-up, relapse rates may
further increase from that demonstrated in this study.
Risk factors for remission, relapse, or persistence
The Woman to Woman Health Study reported here indi-
cated a number of factors associated with worsening vulvo-
dynia outcomes (relapse and/or persistence), including the
presence of provoked pain, more severe pain with or after
intercourse, painwith oral sex or partner touch, higher rating of
worse pain ever, longer duration of pain, or screening positive
for fibromyalgia, interstitial cystitis, or depression, thereby
confirming, in a population-based study, some of the previ-
ously predicted findings and increasing our understanding of
the relationship with comorbid conditions with vulvodynia.
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Little has been written about factors associated with re-
mission of symptoms. We had previously reported on factors
associated with remission in a study of women in a Women’s
Health Registry and found that increased severity of past
vulvar pain,5,6 longer duration of symptoms,5 and the presence
of pain after intercourse6 are associated with less improvement
over time, consistent with our current findings. Nguyen et al.
assessed reports by participants with vulvodynia in a
community-based study about previous periods of no vulvar
pain and found that those with primary vulvodynia were less
likely to report a remission than were those with secondary
vulvodynia, as were those who were either underweight or
obese.26 Those with a longer duration of symptoms were more
likely to have a remission. We, however, found that a longer
duration of symptoms was associated with greater relapse and
greater persistence, and observed no relationship between
primary versus secondary vulvodynia and prognosis.
There are two reasons these results might vary. Based on
the study design, the results of Nguyen et al. reflect remission
among women who have subsequently undergone a re-
lapse—thereby not including characteristics of those who had
a remission without relapse. In addition, their definition of
primary vulvodynia reflected that the woman agreed that she
always had pain on contact. However, if she always had such
pain, it would be consistent with not having had remissions—
a bias that might exist in that study. We defined primary
vulvodynia as whether the woman had had pain at the vulva
with first intercourse and/or first tampon use or, if missing
data, if her pain started before age 20, without a stipulation
that the pain has not remitted at times since onset.
Demographic characteristics, such as age, ethnicity, and
education, were not associated with vulvodynia course, de-
spite the fact that vulvodynia prevalence and incidence differ
somewhat by age and ethnicity.1,8 Further work is needed to
clarify whether these differences in risk of disease, yet lack of
difference in clinical course following onset, can be dem-
onstrated to reflect differing physiology or whether they may
be related to reporting bias or other unmeasured factors.
Strengths and limitations of the study
The natural history of vulvodynia in the general population
can be estimated with less recall bias in a longitudinal
population-based cohort—a major strength of this study. The
use of a validated instrument to predict vulvodynia and the
collection of a substantial number of demographic and po-
tential risk factors over time are similarly strengths. Although
the screening tool used for the vulvodynia diagnosis has been
previously validated,9 the women diagnosed with and with-
out having vulvodynia were not clinically confirmed, and
hence the diagnosis made may differ from that made in the
office setting. In addition, women were not questioned re-
garding the denial of vulvar pain symptoms some had pre-
viously reported. Further study regarding the reasons for
these inconsistencies will add to our understanding of the
interpretation and meaning of this finding.
The population studied was a population-based sample of
women and hence may not reflect the subset of women who
seek care in the office setting—hence the remission/relapse/
persistence rates may differ in a clinical subset, and further
study of women seeking care is needed. Participants received
a token stipend for participation at each survey to encourage
retention, but loss to follow-up did occur. Nonetheless,
80.4% of those completing the initial survey were still par-
ticipating by the 36-month survey. We were also limited in
the evaluation of factors associated with persistence due to
the smaller number of women with this outcome. Continued
identification of new cases and their clinical outcomes would
increase the power of the study to assess these factors.
Conclusions
In summary, remission of symptoms following vulvodynia
diagnosis by a survey-based screening test of a population-
based cohort is very common, but approximately half of those
with remission proceed to relapse within a short period of
time. Consistent reporting of vulvodynia symptoms (persis-
tence) only occurs in the minority of those screening positive.
Factors associated with outcome include several character-
istics of the pain, its duration, and associated comorbid
conditions, but not demographic characteristics.
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